| Literature DB >> 23379414 |
Takashi Yamada1, Takayoshi Kanda, Hiroshi Mori, Kaname Shimokawa, Mitsuo Kagawa, Yuro Shibayama.
Abstract
BACKGROUND: Cell lines are very useful for clinical and basic research. Thus far, only 11 reports have documented the characteristics of ovarian endometrioid adenocarcinoma cell lines in the literature. Due to the scarcity of information, the establishment of an ovarian malignant tumor cell line with distinctive characteristics is particularly important to study this disease. Thus, this study was undertaken to establish and characterize a new human endometrioid adenocarcinoma cell line of the ovary.Entities:
Year: 2013 PMID: 23379414 PMCID: PMC3568727 DOI: 10.1186/1757-2215-6-8
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Figure 1Macroscopic appearance of the original tumor (a, b). The left ovary was a solid tumor.
Figure 2Histology of the original tumor. It shows an endometrioid adenocarcinoma stained with hematoxylin and eosin (HE). (a,bar = 200 μm; b,bar = 50 μm).
Figure 3Phase contrast microscopy. The cells show a pavement-like arrangement and colonies with multilayering. (bar = 200 μm).
Figure 4Cytopathology of cultured NOMH-1 cells. Multinucleated giant cells with spindle-shaped or multipolar cytoplasm are observed by Papanicolaou stain. (bar = 50 μm).
Figure 5Electron micrograph of the original tumor. The cells are attached by desmosome-like junctions (a) and have abundant mitochondria in the cytoplasm (a)(b) and numerous microvilli on the surface (b). (a,b, bar = 1 μm).
Figure 6Growth curve of NOMH-1. The cells grew logarithmically.
Figure 7Distribution of chromosomal numbers in NOMH-1 (5th generation). The modal number is in the hypertriploid range.
Figure 8Karyotype of NOMH-1 (5th generation). Chromosomal analysis showed various abnormalities.
Figure 9Micrograph of a tumor transplanted into a nude mouse. It shows endometrioid adenocarcinoma closely resembling the original tumor. (HE, bar = 50 μm).
Figure 10Immunohistochemical stainings of the original tumor (a, c) and heterotransplanted tumor (b, d) with CEA (a, b) and CA19-9 (c, d). (a, b, c, d; bar = 100 μm).
Chemosensitivity using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay
| | ||
| ACD | >0.1 | 0.08 |
| ADM | 16.5 | 0.4 |
| BLM | >1000 | 3.3 |
| CBDCA | >300 | 37.1 |
| CDDP | 23.2 | 8.5 |
| CPA | >10 | 4.3 |
| CPT-11 | 1.79 | 0.05 |
| 5-FU | 497 | 15.3 |
| MMC | 6.5 | 2.4 |
| MTX | >300 | 3 |
| PTX | 5.1 | 11.8 |
| VCR | 15 | 0.1 |
| VLB | 16 | 0.15 |
| VP-16 | 197 | 13 |
EC50, effective concentration for 50% kill; PPC, peak plasma concentration taken intravenously; ACD, actinomycin D; ADM, doxorubicin; BLM, bleomycin; CBDCA, carboplatin; CDDP, cisplatin; CPA, 4-hydroperoxy-cyclophosphamide; CPT-11, irinotecan hydrochloride; 5-FU, 5-fluorouracil; MMC, mitomycin C; MTX, methotrexate; PTX, paclitaxel; VCR, vincristine; VLB, vinblastine; VP-16, etoposide;.
Figure 11Dose response curve for paclitaxel. The EC50 value of paclitaxel is 5.1.
Cell lines from ovarian endometrioid adenocarcinoma
| #2774 (1978) | - | ascites | 66-68 | - | Yes | - | - |
| - (1983) | 47 | ascites | 103 (51–402) | 74.4 | Yes | - | - |
| OVK18 (1983) | 49 | ascites | 47 (mode) | 48 | Yes | - | ER(−), PgR(−) |
| HMOA (1986) | 57 | ovarian tumor | 46-47 (mode) | 72, 58 | Yes | - | production of CA125 |
| HNOA (1986) | 71 | transplanted tumor | 46-47 (mode) | 28, 24 | Yes | - | CA125(−) |
| HOC-I (1989) | 40 | recurrent tumor | 46 (44–49) | 75 | Yes | ER(−) | ER(−), production of CA125, TPA |
| COV362 (1993) | - | - | 69 (67–73) | - | - | - | - |
| SIB-1 (1994) | 39 | pleural effusion | 46 (43–54) | - | - | HMFG-2, CA125 | serum free medium |
| SNU-251 (1997) | 47 | ascites | - | 46 | - | - | CA125(−), CEA(−), p53, BRCA1, hMLH1 mutation(+) |
| SNU-563 (1997) | 54 | ovarian tumor | - | 67 | - | - | p53 mutation(+) |
| NOE (2007) | 46 | tumor fluid | 65-74 | - | Yes | - | ER(+) |
| NOMH-1 | 44 | ovarian tumor | 73-80 | 273 | Yes | CA19-9, CEA, ER(−), PgR(−) | production of CA19-9, CEA, TPA |
DT; doubling time (hour).